Clinical trials: Erythropoietin
Healthy
Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects
The primary purpose of this study is to compare the PK parameters of a single dose of a test tablet formulation of AKB-6548 relative to a single dose of the reference AKB-6548 tablet formulation, both treatments administered…
- Trial name
- NCT02412449
- Testing
- AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Anemia, Neoplasms
Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)
The main purpose of this study is to evaluate the safety and efficacy (% response) of epoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer.
- Trial name
- NCT00398749
- Testing
- Epoetin alfa
- Volunteers
- 1,927 people
- Sponsor
- Janssen-Cilag B.V.
Heart; Dysfunction Postoperative, Cardiac Surgery, Anemia, Iron-Deficiency
Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery
Pre-treatment of patients with erythropoietin subcutaneously and iron supplement intravenously, in order to create a clinical pathway to minimize transfusion of red blood cells in a selected group of cardiac patients with an…
- Trial name
- NCT02210949
- Testing
- Erythropoietin subcutaneously and Iron intravenously
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Anemia
A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B
This study will examine the efficacy, safety and effect on hemoglobin levels, of once weekly subcutaneous injections of epoetin beta (30,000 IU) in anemic participants with non-Hodgkin's lymphoma, chronic lymphocytic leukemia or…
- Trial name
- NCT02608060
- Testing
- Epoetin Beta
- Where
- 2 sites in Venezuela
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Acute Myocardial Infarction
Anti-Restenosis After AMI by Erythropoietin
The EPOC-AMI study is to assess the safety and the efficacy of systemic administration of erythropoietin for inhibition of neointimal hyperplasia after stent implantation in the patients with acute myocardial infarction
- Trial name
- NCT00423020
- Testing
- Erythropoietin
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Kyoto Prefectural University of Medicine
Oral Lichen Planus
Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus
The purpose of this study is to compare the clinical efficacy of erythropoietin gel containing a solution of 4000 units with triamcinolone acetonide 0.1% gel in the treatment of symptomatic oral lichen planus (OLP)
- Trial name
- NCT06135259
- Testing
- erythropoietin, Triamcinolone acetonide
- Volunteers
- 18 people
- Sponsor
- Ain Shams University
Kidney Failure, Chronic, Drug Resistance
REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial
A strategy for optimizing erythropoietin therapy in patients with erythropoietin resistance. A multi-centered, open-label, randomized, controlled trial.
- Trial name
- NCT00319150
- Testing
- erythropoietin
- Where
- 7 sites in Canada
- Volunteers
- 6 people
- Sponsor
- Queen's University
Anemia
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
Pharmacokinetic/Pharmacodynamic Study of 3 Epoetin Alfa Formulations in Single Subcutaneous Doses Administered to Healthy Volunteers SPONSOR Biosidus S.A.
- Trial name
- NCT03822884
- Testing
- Epoetin Alfa 40000 UNT/ML
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bio Sidus SA
Anemia, Fatigue
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy. It may also help relieve fatigue in patients with anemia.
- Conditions
- Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00258440
- Testing
- Weekly procrit dosing, Interval Dosing
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- OHSU Knight Cancer Institute
Anemia
Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients
This is a study to investigate the clinical efficacy and safety of epoetin beta 36,000 IU compared with placebo when administrated subcutaneously (s.c.) once-weekly for 12 weeks to anemic patients with lung cancer or gynecologic…
- Trial name
- NCT00628043
- Testing
- epoetin beta
- Where
- 6 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Chugai Pharmaceutical
Chemotherapy, Anemia
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks
The purpose of this study is to determine the effectiveness and safety of epoetin alfa at a starting dose of 60,000 Units (U) once every week (QW) to a target hemoglobin (Hb) of 12 g/dL (Initiation Phase), followed by a dose of…
- Conditions
- Chemotherapy, Anemia, Cancer
- Trial name
- NCT00337948
- Testing
- Epoetin alfa
- Volunteers
- 129 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Unspecified Adult Solid Tumor, Protocol Specific
Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors
RATIONALE: Epoetin beta may cause the body to make more red blood cells and may prevent or reduce side effects in patients undergoing chemotherapy for solid tumors.
- Trial name
- PLATON (NCT00875004)
- Testing
- epoetin beta, systemic chemotherapy, quality-of-life assessment
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Complication of Renal Dialysis
Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED)
The specific aim of this trial is to determine whether initiating moderate- or high-intensity atorvastatin therapy in hemodialysis patient not previously on a statin reduces inflammation and lowers average Epogen utilization.
- Trial name
- ARChIVED (NCT02764736)
- Testing
- Atorvastatin
- Sponsor
- Albert Einstein Healthcare Network
Anemia, Kidney Failure
Erythropoietin Resistance in Anemia of Chronic Kidney Disease
Our goal of this pilot project is to identify inflammatory biomarkers that correlate with epo-resistance among CKD patients.
- Conditions
- Anemia, Kidney Failure, Erythropoietin
- Trial name
- NCT00526747
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Stomach Neoplasms, Rectal Neoplasms
Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery
The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa on the reduction in red blood cell transfusions needed in gastric cancer patients and rectal cancer patients undergoing a treatment plan of…
- Trial name
- NCT00036400
- Testing
- epoetin alfa
- Volunteers
- 60 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Chemotherapy
Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia
The purpose of this study is to compare hemoglobin (Hgb) response rates between epoetin alfa (PROCRIT; 40,000 Units (U) SC weekly) and darbepoetin alfa (ARANESP; 200 mcg every other week) in anemic cancer patients receiving…
- Trial name
- NCT00315484
- Testing
- Epoetin alfa and Darbepoetin alfa
- Volunteers
- 358 people
- Sponsor
- Ortho Biotech Products, L.P.
Anemia, Anaemia
Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia
The study will evaluate the ability of GSK1278863 to increase the hemoglobin (Hgb) concentration, or maintain it within the target range, and the safety and efficacy of GSK1278863 over 16 weeks of treatment, in…
- Trial name
- NCT02075463
- Testing
- GSK1278863
- Where
- 10 sites in United States
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Anemia, Leukemia
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
RATIONALE: Thalidomide may stop or slow the growth of cancer cells. Epoetin alfa may stimulate red blood cell production. Combining thalidomide with epoetin alfa may improve anemia, decrease the need for blood transfusions, and…
- Conditions
- Anemia, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00053001
- Testing
- epoetin alfa, thalidomide
- Where
- 2 sites in United States
- Sponsor
- Fallon Clinic
HIV Infections, Cytopenias
The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT
To determine the safety and efficacy of erythropoietin administered subcutaneously to AIDS patients with anemia secondary to their disease and/or concomitant zidovudine (AZT) therapy.
- Trial name
- NCT00002302
- Testing
- Epoetin alfa
- Where
- 2 sites in United States
- Sponsor
- Ortho Pharmaceuticals
Anemia, Myelodysplastic Syndromes
Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. Epoetin alfa may stimulate red blood cell production and be an effective treatment for anemia in patients with myelodysplastic syndrome.
- Trial name
- NCT00003681
- Testing
- epoetin alfa, amifostine trihydrate
- Where
- 12 sites in Austria, Belgium and 5 more
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC